Clyde Launches New Contractility Service – CellOPTIQ®-X
October 26, 2016
Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma
Newhouse, United Kingdom, October 26, 2016 – Clyde Biosciences today announced the launch of a new service to serve the needs of its global pharma
Brighton, UK, October 17, 2016 – Enterprise Therapeutics Ltd, a drug discovery company dedicated to the research and development of novel therapies for the treatment
Edinburgh, Scotland, October 7, 2016 – At the OBN Awards 2016 dinner in Oxford last night, Edinburgh Molecular Imaging were awarded the Best Emerging Medtech Company
LOUISVILLE, Ky., Aug. 8, 2016 – Apellis Pharmaceuticals, Inc., a clinical stage complement immunotherapy company, announced today the expansion of its executive team with the addition of Dr.
A pioneering new company based on Selvita research and utilizing novel immunological approaches to disease Edinburgh, Scotland, July 28, 2016: Epidarex Capital today announces the
LOUISVILLE, Ky., June 23, 2016 – Apellis Pharmaceuticals, Inc. today announced positive results from two Phase 1 clinical trials of its complement C3 inhibitor, APL-2.
Glasgow, Scotland, UK, 20th June 2016: Mironid Ltd, a leader in cell signalling directed drug development, today announced the closing of its Series A funding
Caldan Therapeutics, a spin-out company from the Universities of Glasgow and Southern Denmark, which specialises in developing novel therapeutics targeting free fatty acid receptors for
By Gareth Mackie, The Scotsman A university spin-out that specialises in potential treatments for type 2 diabetes has bolstered its boardroom in the wake of
Edinburgh and Paris, April 6th, 2016 – Edinburgh Molecular Imaging Ltd (EM Imaging) and Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) today announced a clinical